The present invention relates to a pharmaceutical antiretroviral composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition and the use of such composition in medicine, particularly for the prophylaxis and/or treatment of diseases caused by retroviruses.
本发明涉及一种药物抗逆转录病毒组合物,包括(i)从
拉米夫定和
恩替卡韦中选择的核苷类逆转录酶
抑制剂,(ii)延长释放的
奈韦拉平,以及(iii)
替诺福韦;一种制备该组合物的方法以及在医学上使用该组合物,特别是用于预防和/或治疗由逆转录病毒引起的疾病。